BG105254A - Heterocyclic compounds as inhibitors of rotamase enzymes - Google Patents

Heterocyclic compounds as inhibitors of rotamase enzymes

Info

Publication number
BG105254A
BG105254A BG105254A BG10525401A BG105254A BG 105254 A BG105254 A BG 105254A BG 105254 A BG105254 A BG 105254A BG 10525401 A BG10525401 A BG 10525401A BG 105254 A BG105254 A BG 105254A
Authority
BG
Bulgaria
Prior art keywords
aryl
alkyl
het
optionally substituted
inhibitors
Prior art date
Application number
BG105254A
Other languages
Bulgarian (bg)
English (en)
Inventor
Mark KEMP
Michael Palmer
Mark SANNER
Martin Wythes
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG105254A publication Critical patent/BG105254A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105254A 1998-07-21 2001-02-14 Heterocyclic compounds as inhibitors of rotamase enzymes BG105254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815880.1A GB9815880D0 (en) 1998-07-21 1998-07-21 Heterocycles
PCT/IB1999/001211 WO2000005232A1 (fr) 1998-07-21 1999-06-28 Composes heterocycliques inhibiteurs d'enzymes rotamase

Publications (1)

Publication Number Publication Date
BG105254A true BG105254A (en) 2001-10-31

Family

ID=10835920

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105254A BG105254A (en) 1998-07-21 2001-02-14 Heterocyclic compounds as inhibitors of rotamase enzymes

Country Status (45)

Country Link
US (2) US6372736B1 (fr)
EP (1) EP1100797B1 (fr)
JP (2) JP3795329B2 (fr)
KR (2) KR100450008B1 (fr)
CN (3) CN1174978C (fr)
AP (1) AP2001002046A0 (fr)
AR (1) AR019427A1 (fr)
AT (1) ATE233261T1 (fr)
AU (1) AU765925B2 (fr)
BG (1) BG105254A (fr)
BR (1) BR9912330A (fr)
CA (1) CA2338214C (fr)
CO (1) CO5080782A1 (fr)
CR (1) CR6073A (fr)
DE (1) DE69905582T2 (fr)
DK (1) DK1100797T3 (fr)
DZ (1) DZ2851A1 (fr)
EA (1) EA003513B1 (fr)
EE (1) EE200100044A (fr)
ES (1) ES2191484T3 (fr)
GB (1) GB9815880D0 (fr)
GE (1) GEP20033028B (fr)
GT (1) GT199900115A (fr)
HK (1) HK1039779A1 (fr)
HN (1) HN1999000106A (fr)
HR (1) HRP20010052A2 (fr)
HU (1) HUP0103413A3 (fr)
ID (1) ID26991A (fr)
IL (1) IL140244A0 (fr)
IS (1) IS5790A (fr)
MA (1) MA24936A1 (fr)
MY (1) MY118222A (fr)
NO (1) NO20010322L (fr)
NZ (2) NZ522270A (fr)
OA (1) OA11585A (fr)
PA (1) PA8478501A1 (fr)
PE (1) PE20001037A1 (fr)
PL (1) PL345734A1 (fr)
SI (1) SI1100797T1 (fr)
SK (1) SK772001A3 (fr)
SV (1) SV1999000102A (fr)
TN (1) TNSN99147A1 (fr)
TR (1) TR200100135T2 (fr)
TW (1) TWI229672B (fr)
WO (1) WO2000005232A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
BR9915013A (pt) 1998-11-03 2001-08-07 Basf Ag Composto, uso dos mesmos, processo para preparar os mesmos, droga, e, método para detecção in vitro para inibidores parp
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
DK1778637T3 (da) * 2004-06-29 2012-06-18 Aventis Pharma Inc FKBP-bindingssammensætninger og farmaceutisk anvendelse deraf
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
EP1957477B1 (fr) * 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides a substitution phenyle en position 2, utilises comme inhibiteurs de la parp
TW200736229A (en) * 2005-11-15 2007-10-01 Abbott Lab Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EP3205644A1 (fr) 2005-12-29 2017-08-16 Celtaxsys Inc. Dérivés de diamine en tant qu'inhibiteurs d'hydrolase a4 de leucotriène
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
WO2007091106A2 (fr) 2006-02-10 2007-08-16 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
ATE553104T1 (de) * 2006-05-02 2012-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
AU2007338793B2 (en) * 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
AR065628A1 (es) * 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
CN101678107A (zh) * 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010083199A1 (fr) * 2009-01-19 2010-07-22 Abbott Laboratories Inhibiteurs benzthiazole de la poly(adp-ribose)polymérase
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
EP2970309A4 (fr) 2013-03-14 2016-11-09 Celtaxsys Inc Inhibiteurs de la leucotriène a4 hydrolase
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2968265A4 (fr) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibiteurs de la leucotriène a4 hydrolase
AU2015264336B2 (en) * 2014-05-19 2018-08-30 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds
EP3801559A4 (fr) 2018-05-31 2022-03-02 Celltaxis, LLC Procédé de réduction d'exacerbations pulmonaires chez des patients atteints d'une maladie respiratoire
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
JPS6428245A (en) 1987-07-22 1989-01-30 Sumitomo Electric Industries Production of fluoride glass
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
KR20040062640A (ko) 2004-07-07
TNSN99147A1 (fr) 2005-11-10
EA200100052A1 (ru) 2001-06-25
ATE233261T1 (de) 2003-03-15
GB9815880D0 (en) 1998-09-16
ES2191484T3 (es) 2003-09-01
SI1100797T1 (en) 2003-06-30
HK1039779A1 (zh) 2002-05-10
HN1999000106A (es) 1999-11-11
CR6073A (es) 2004-04-29
PA8478501A1 (es) 2000-05-24
DZ2851A1 (fr) 2004-02-04
NO20010322L (no) 2001-03-15
HRP20010052A2 (en) 2001-12-31
MA24936A1 (fr) 2000-04-01
AU4285899A (en) 2000-02-14
US6562964B1 (en) 2003-05-13
OA11585A (en) 2004-07-26
EA003513B1 (ru) 2003-06-26
MY118222A (en) 2004-09-30
AP2001002046A0 (en) 2001-03-31
US6372736B1 (en) 2002-04-16
WO2000005232A1 (fr) 2000-02-03
GT199900115A (es) 2001-01-10
TR200100135T2 (tr) 2001-06-21
JP2004002374A (ja) 2004-01-08
JP3795329B2 (ja) 2006-07-12
EE200100044A (et) 2002-06-17
HUP0103413A3 (en) 2002-10-28
SV1999000102A (es) 2000-07-06
GEP20033028B (en) 2003-07-25
KR20010071013A (ko) 2001-07-28
CN1174978C (zh) 2004-11-10
CN1611499A (zh) 2005-05-04
AR019427A1 (es) 2002-02-20
HUP0103413A2 (hu) 2002-05-29
CA2338214C (fr) 2006-08-01
PE20001037A1 (es) 2000-10-11
DE69905582D1 (de) 2003-04-03
CN1310718A (zh) 2001-08-29
CN1511837A (zh) 2004-07-14
DK1100797T3 (da) 2003-04-22
TWI229672B (en) 2005-03-21
DE69905582T2 (de) 2003-09-04
ID26991A (id) 2001-02-22
IS5790A (is) 2000-12-22
JP2002521382A (ja) 2002-07-16
NO20010322D0 (no) 2001-01-19
CA2338214A1 (fr) 2000-02-03
KR100468185B1 (ko) 2005-01-26
BR9912330A (pt) 2001-04-17
KR100450008B1 (ko) 2004-09-24
NZ508838A (en) 2002-12-20
AU765925B2 (en) 2003-10-02
IL140244A0 (en) 2002-02-10
CO5080782A1 (es) 2001-09-25
SK772001A3 (en) 2001-12-03
EP1100797A1 (fr) 2001-05-23
NZ522270A (en) 2004-03-26
PL345734A1 (en) 2002-01-02
EP1100797B1 (fr) 2003-02-26

Similar Documents

Publication Publication Date Title
BG105254A (en) Heterocyclic compounds as inhibitors of rotamase enzymes
PT810209E (pt) Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NO992770L (no) Nye heterocyklisk substituerte benzamider og deres anvendelse ved bekjempelse av sykdommer
AP9901479A0 (en) Heterocyclic compounds as inhibitors of rotamase enzymes.
DE69332792D1 (de) 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
MX9701685A (es) Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
BG104569A (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
ES2177816T3 (es) Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas.
DE69329084D1 (de) Benzoxazepin-Derivate als Cholinesterase-Inhibitoren
FR2725719B1 (fr) Diazepino-indoles inhibiteurs de phosphodiesterases iv
MX14210A (es) Procedimiento para preparar inhibidores no-peptidicos de renina
ES2169044T3 (es) Nuevos esteres de acido nicotinico.
MX9800705A (es) Compuestos heterociclicos, composiciones para tratar isquemia de miocardio que los contiene, y procedimiento para su preparacion.
EP0799040A4 (fr) Thioxanthines trisubstituees